Cancer drug Keytruda, page-2

That's a tricky one Manfred. The funding of the PBS is limited. They try to negotiate to access new drugs at cheaper rates. Sometimes big pharma plays ball and sometimes it doesn't. It's a fair bet that there are or have been talks between PBAC and Merck on including the drug but given Merck is still discovering more uses for the drug they may not be anxious to settle on a lower price just yet. Paying up for Keytruda may mean that the PBS has insufficient funding for other new drugs. By all means petition so that Hunt is prompted to inquire but don't take things for granted.